MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis

被引:275
作者
Rosmorduc, O
Hermelin, B
Poupon, R
机构
[1] Hop St Antoine, Serv Hepatogastroenterol, Assistance Publ Hop Paris, F-75571 Paris, France
[2] Hop St Antoine, Lab Commun Biol Mol Federat Biochim, Assistance Publ Hop Paris, F-75571 Paris, France
关键词
D O I
10.1053/gast.2001.23947
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background&Aims: Many studies indicate that gallstone susceptibility has genetic components, MDR3 is the phosphatidylcholine translocator across the hepatocyte canalicular membrane. Because phospholipids are a carrier and a solvent of cholesterol in hepatic bile, we hypothesized that a defect in the MDR3 gene could be the genetic basis for peculiar forms of cholesterol gallstone disease, in particular those associated with symptoms and cholestasis without evident common bile duct stone. Methods: We studied 6 adult patients with a peculiar form of cholelithiasis. MDR3 gene sequence was determined by reverse-transcription polymerase chain reaction amplification of mononuclear cell RNAs followed by direct sequencing, Hepatic bile was analyzed in 2 patients. Results: All patients shared the following features: at least 1 episode of biliary colic, pancreatitis, or cholangitis; biochemical evidence of chronic cholestasis; recurrence of symptoms after cholecystectomy; presence of echogenic material in the intrahepatic bile ducts; and prevention of recurrence by ursodeoxycholic acid therapy. Hepatic bile composition showed a high chotesterol/phospholipid ratio and cholesterol crystals. In all patients, we found MDR3 gene mutations involving a conserved amino acid region. Conclusions: These preliminary observations suggest that MDR3 gene mutations represent a genetic factor involved in this peculiar form of cholesterol gallstone disease in adults. They require further studies to assess the prevalence of MDR3 gene defects in symptomatic and silent cholesterol gallstone disease.
引用
收藏
页码:1459 / 1467
页数:9
相关论文
共 38 条
[31]   PHOSPHATIDYLCHOLINE TRANSLOCASE - A PHYSIOLOGICAL-ROLE FOR THE MDR2 GENE [J].
RUETZ, S ;
GROS, P .
CELL, 1994, 77 (07) :1071-1081
[32]   GALLSTONE RECURRENCE AFTER SHOCK-WAVE THERAPY [J].
SACKMANN, M ;
NILLER, H ;
KLUEPPELBERG, U ;
VONRITTER, C ;
PAULETZKI, J ;
HOLL, J ;
BERR, F ;
NEUBRAND, M ;
SAUERBRUCH, T ;
PAUMGARTNER, G .
GASTROENTEROLOGY, 1994, 106 (01) :225-230
[33]   HOMOZYGOUS DISRUPTION OF THE MURINE MDR2 P-GLYCOPROTEIN GENE LEADS TO A COMPLETE ABSENCE OF PHOSPHOLIPID FROM BILE AND TO LIVER-DISEASE [J].
SMIT, JJM ;
SCHINKEL, AH ;
ELFERINK, RPJO ;
GROEN, AK ;
WAGENAAR, E ;
VANDEEMTER, L ;
MOL, CAAM ;
OTTENHOFF, R ;
VANDERLUGT, NMT ;
VANROON, MA ;
VANDERVALK, MA ;
OFFERHAUS, GJA ;
BERNS, AJM ;
BORST, P .
CELL, 1993, 75 (03) :451-462
[34]  
STIEHL A, 1995, J HEPATOL, V23, P283
[35]   LITHOTRIPSY PLUS URSODIOL IS SUPERIOR TO URSODIOL ALONE FOR CHOLESTEROL GALLSTONES [J].
TINT, GS ;
DYRSZKA, H ;
SANGHAVI, B ;
PATEL, G ;
PATEL, S ;
SHEFER, S ;
SALEN, G .
GASTROENTEROLOGY, 1992, 102 (06) :2042-2049
[36]   Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: A cohort analysis [J].
Tomida, S ;
Abei, M ;
Yamaguchi, T ;
Matsuzaki, Y ;
Shoda, J ;
Tanaka, N ;
Osuga, T .
HEPATOLOGY, 1999, 30 (01) :6-13
[37]  
Van Dyke RW, 1996, HEPATOLOGY TXB LIVER, V2, P1734
[38]  
Wang DQH, 1999, J LIPID RES, V40, P2066